Duke APOL1 Research Biorepository

Status Recruiting

Clinical Trial Summary

The Duke ApoL1 Nephropathy Biorepository aims to address needs within non-diabetic kidney failure research by utilizing existing and, when necessary, developing new infrastructure to support the consent of patients and the collection of dedicated samples for ApoL1 Nephropathy biorepository. The mutations in ApoL1 gene that are strongly associated with kidney disease are only present in individuals of recent African ancestry (i.e., black people). Caucasians do not have these ApoL1 mutations nor the associated kidney disease. Therefore, majority of subjects recruited for this study will be self-identified African Americans, Afro-Caribbean and other black individual. Study subjects will include individuals with end stage kidney disease and those without any clinical evidence of kidney disease. Additionally, healthy black adults with no known history of kidney disease will be recruited as controls in this study because they are the only group that can fill this role.

Clinical Trial Description

The risk of end stage kidney failure among African Americans is 4 times that of Caucasian Americans. This excess risk of kidney failure is largely attributable to mutations in apolipoprotein L1 gene. While 10-15% of African Americans in the United States possess kidney disease-associated ApoL1 mutations, nearly 40% of African Americans on dialysis have these mutations. There are significant gaps in the understanding of the pathophysiology of ApoL1-nephropathy. Only some of the people with ApoL1 mutations develop kidney failure. The pathways that link ApoL1 mutations with end stage kidney failure are not understood. Because kidney biopsy is generally obtained from patients with evidence of kidney disease-whose kidneys have experienced significant damage and sclerosis-access to the relevant kidney cells is very limited. However, recent advancements in biomedical research have made it possible to develop kidney-like cells from inducible pluripotent stem cells (iPSCs) which were derived from blood cells of individuals. This innovative technique will allow us to generate iPSC-derived cells from the blood of individuals who have developed ApoL1-nephropathy for the purpose studying them in research lab so as to decipher the cellular mechanism of their kidney failure. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04160507
Study type	Observational
Source	Duke University
Contact	Opeyemi Olabisi, MD/PHD
Phone	919-660-6987
Email	opeyemi.olabisi@duke.edu
Status	Recruiting
Phase
Start date	December 13, 2019
Completion date	November 15, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04319185` - Assisted Peritoneal Dialysis: A Feasibility Study	N/A
Recruiting	`NCT06056739` - Alio WEAR Study: Long-term Wear of the Alio Platform	N/A
Recruiting	`NCT05311956` - Pain Reduction Using NEurostimulation Study	N/A
Enrolling by invitation	`NCT05485961` - Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis	Phase 2/Phase 3
Completed	`NCT02939586` - The Effect of Haemodialysis in Sleep Apnoea	N/A
Completed	`NCT00792454` - Reduction of Mortality Prior to and During the First 90 Days of Dialysis Through a Renal Rehabilitation Program	N/A
Recruiting	`NCT03586518` - Validating Novel, Non-contrast Cardiac MRI Imaging in Haemodialysis Patients
Completed	`NCT02513303` - Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes	Phase 3
Recruiting	`NCT05642156` - Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis	N/A
Not yet recruiting	`NCT05774392` - An Observational Study of Patients With Chronic Kidney Disease
Completed	`NCT01877863` - The Effect of Intradialytic Exercise on the Functional Capacity of Hemodialysis Patients	N/A
Completed	`NCT01859871` - Evaluation of a Website on Living Kidney Donation for Hispanics	N/A
Completed	`NCT00649298` - A Clinical Trial of IntensiVE Dialysis	Phase 4
Recruiting	`NCT05836220` - Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-2	Phase 3
Completed	`NCT04912024` - Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy Study
Completed	`NCT01530945` - Mapping Multidimensional Illness Trajectories of Patients With End-stage Kidney Disease	N/A
Completed	`NCT04815850` - Phenotyping Seroconversion Following Vaccination Against COVID-19 in Patients on Haemodialysis Study
Recruiting	`NCT05738330` - Symptom Monitoring in Hemodialysis	N/A
Completed	`NCT02475551` - Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation	Phase 2
Completed	`NCT00976846` - Investigation of Performance and Compatibility of the Baxter Dialyzer Xenium XPH 210 During On-line Hemodiafiltration	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Duke APOL1 Research Biorepository — DARB

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms